MDxHealth (NASDAQ:MDXH) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of MDxHealth (NASDAQ:MDXH) to a sell rating in a research note issued to investors on Saturday morning.

Several other equities analysts also recently issued reports on the stock. William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. BTIG Research reduced their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. TD Cowen restated a “buy” rating and issued a $1.50 price objective (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Finally, Lake Street Capital set a $3.00 target price on MDxHealth and gave the stock a “buy” rating in a report on Friday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $2.83.

MDxHealth Trading Up 74.9%

NASDAQ:MDXH opened at $0.81 on Friday. The stock’s 50-day moving average is $0.47 and its 200-day moving average is $1.78. MDxHealth has a 1-year low of $0.40 and a 1-year high of $5.33. The stock has a market cap of $40.00 million, a P/E ratio of -1.12 and a beta of 1.42.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The business had revenue of $27.21 million during the quarter, compared to the consensus estimate of $26.14 million. As a group, equities analysts forecast that MDxHealth will post -0.6 EPS for the current year.

Institutional Trading of MDxHealth

A number of large investors have recently bought and sold shares of MDXH. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth in the 3rd quarter worth about $53,000. Russell Investments Group Ltd. bought a new stake in shares of MDxHealth during the 3rd quarter valued at about $461,000. Kennedy Capital Management LLC bought a new stake in shares of MDxHealth during the 3rd quarter valued at about $1,826,000. Panoramic Capital LLC acquired a new stake in MDxHealth during the third quarter worth approximately $721,000. Finally, Bank of America Corp DE grew its stake in MDxHealth by 5,164.0% during the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after purchasing an additional 14,769 shares during the period.

MDxHealth News Roundup

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: MDxHealth reported second-quarter revenue of $27.2 million, up 16% year over year and above the approximately $26.1 million analyst estimate. The company’s $0.18 per-share loss was slightly better than the $0.19 consensus cited by MarketBeat, although another estimate tracked by Zacks showed a larger expected loss of $0.12. MDxHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed an optimistic FY 2026 revenue outlook of $110 million to $115 million, well above the roughly $98.8 million consensus estimate. This suggests management expects continued commercial momentum. MDxHealth Earnings Report
• Positive Sentiment: Management discussed the results and outlook during its second-quarter earnings call, giving investors additional detail on the company’s operating performance and growth plans. MDxHealth Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Trading in MDXH was temporarily paused several times under the exchange’s Limit Up-Limit Down mechanism. The halts do not represent a fundamental company announcement, but they underscore unusually high volatility and speculative trading activity.
• Negative Sentiment: MDxHealth agreed to raise $20 million through a direct share offering. The added funding may support operations and growth, but issuing new shares can dilute existing shareholders and may be contributing to the sharp price swings. MDxHealth Raises $20 Million in Direct Share Offering

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.